Invivyd's NVD-200 shows in vitro neutralizing activity against SARS-CoV-2 omicron variants
Sep. 13, 2022
Invivyd Inc. (formerly Adagio Therapeutics Inc.) has generated multiple next-generation candidate antibodies for the prevention and treatment of COVID-19, including two molecules designated for near-term clinical development in combination as NVD-200.